PT-141 HA Peptide Spray - Lyophilized - 99%+

$194.99
PT-141 HA Peptide Spray - Lyophilized - 99%+
Availability:
In Stock
Bulk Pricing:
Buy in bulk and save

Bulk discount rates

Below are the available bulk discount rates for each individual item when you purchase a certain amount

  • Buy 2 - 2 and get 10% off
  • Buy 3 or above and get 15% off
Adding to cart… The item has been added

Lyophilized Peptides: These peptides are freeze-dried, a process that not only extends shelf life but also preserves the purity and integrity of the peptides during storage.

Non-Lyophilized Peptides: Offered as a dry powder, these peptides, while not as extensively processed as lyophilized peptides, still maintain a high level of purity. Their stability, though not as enhanced as in lyophilized form, is sufficient for maintaining quality under proper storage conditions.

98.5% vs. 99% Purity: Both grades go through our lyophilization process in our US-based facility and are tested for quality at a third party lab. While the 99%+ purity grade is our highest reference grade product line, the 98.5% purity variants still exceed US pharmaceutical standards.

Product Overview

Compound: PT‑141 (Bremelanotide) Nasal Spray

Format: Metered-dose nasal spray (~10 mg/mL)

Contents: 40 sprays per bottle (10 mg/spray)

Storage: Store at room temperature; refrigerate after opening.

For research/lab use only. Not for human administration.

Batch-specific third-party analysis ensures identity, purity, and stability. Email providers@theratideusa.com for your COA.

PT‑141 (Bremelanotide) is a cyclic heptapeptide agonist of melanocortin receptors (MC3R/MC4R) that works via central nervous system pathways rather than vascular mechanisms :contentReference[oaicite:1]{index=1}.

  • Erectile Response: Intranasal PT‑141 enhanced erections, particularly when combined with sildenafil, with good tolerability in clinical trials :contentReference[oaicite:2]{index=2}.
  • Onset & Tolerance: Effects appeared within 30–45 minutes, with common side effects of flushing, nausea, and transient blood pressure increase :contentReference[oaicite:3]{index=3}.
  • FDA Approval: The subcutaneous formulation (Vyleesi) is approved (2019) for hypoactive sexual desire disorder (HSDD) in premenopausal women :contentReference[oaicite:4]{index=4}.

How quickly does the nasal spray work?
Typically within 30–45 minutes after use :contentReference[oaicite:5]{index=5}.

Is it safe?
Well-tolerated in clinical settings. Mild flushing and nausea are common; blood pressure should be monitored during research protocols :contentReference[oaicite:6]{index=6}.

Can it be used alone?
Yes—effective alone or in combination with PDE5 inhibitors, though combinations showed stronger responses :contentReference[oaicite:7]{index=7}.

Is this product FDA-approved?
The nasal spray form is not approved for human use. Only the injectable form (Vyleesi) is FDA-approved for women’s sexual health :contentReference[oaicite:8]{index=8}.

This product is sold for research purposes only and not intended for human use or as a dietary supplement. Please review our Terms & Conditions before ordering.

Safety Information: Keep out of reach of children. Use only with appropriate laboratory protocols.

FDA Notice: These statements have not been evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.

All products offered by TheraTide USA are strictly intended for research and development purposes only.

None of the statements on this website have been evaluated by the U.S. Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease.

TheraTide USA is a research chemical supplier. We are not a compounding pharmacy or a chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act.